PMC:7696151 / 44826-45256
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1248 | 20-28 | Species | denotes | patients | Tax:9606 |
1249 | 416-424 | Species | denotes | patients | Tax:9606 |
1257 | 42-45 | Chemical | denotes | HCQ | MESH:D006886 |
1261 | 197-201 | Disease | denotes | pain | MESH:D010146 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T71 | 197-201 | Phenotype | denotes | pain | http://purl.obolibrary.org/obo/HP_0012531 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T291 | 0-430 | Sentence | denotes | In the first study, patients treated with HCQ (400 mg/day for 6 months and 200 mg/day for the next 6 months) experienced time-dependent statistically significant improvements in morning stiffness, pain, swollen joints, together with a decrease in blood levels of immunoglobulin M and erythrocyte sedimentation rate [77], while, in the second study, the same treatment was associated to no erosions in the 12% of the patients [78]. |